IAT7, have been purified to homogeneity. Analysis of a polypeptide profile of the recombinant phage obtained by SDS/polyacrylamide-gel electrophoresis showed that IATl exhibited a /I-galactosidase fusion polypeptide with an M , 10000 higher than that of the normal p-galactosidase product. No fusion proteins were detected in the other three recombinants but neither was the normal p-galactosidase polypeptide present. This suggests that fusion products had been formed but were susceptible to proteolytic degradation.
The reported subunit M , (52000) of the A transferase isolated from human plasma (Nagai et al., 1 9 7 8~) predicts a mRNA of at least 1.5 kb. The cDNA inserts excised from the vector by EcoRI digestion were all smaller than this (ATI, 700bp; AT2, 400bp; AT4, 350bp; AT7, 600bp), indicating that none could correspond to the intact mRNA for the A transferase. Since the inserts were of different sizes it is also improbable that they all represent the same cDNA and indeed preliminary cross-hybridization experiments suggest that they do not share sequence homology.
The cDNA inserts from the recombinants have been subcloned into the plasmid vector pUC8 (Maniatis et a/., 1982) . One clone (pAT4) has been used to prepare a "P-labelled probe. This probe gave a single band on hybridization with a restriction enzyme digest of whole human DNA and reacted only weakly with rodent DNA. At present our attention is focused on the chromosomal assignment of this probe using DNA from rodent/human somatic cell hybrids, containing or lacking human chromosome 9. The pattern of expression of mRNA in different tissues in which the A transferase is known either to be expressed or to be absent is also being examined by Northern blot analysis. As no amino acid sequence data is available on the human A transferase, or on a mammalian equivalent, nucleotide sequencing of the recombinants will not be immediately useful for their identification but will reveal whether the inserts correspond to any human DNA sequences that have already been cloned.
Poluncl
Alterations of serum glycosyltransferase levels have been described in a number of neoplastic diseases including leukaemias and lymphomas (for references see Weiser et ul., 1982) . Conflicting results were reported for plasma or serum cc-2-~-fucosyltransferase (EC 2.4.1.69) activity in acute myelogenous leukaemia (AML) patients. In some Ahbrcviations used: AML. acute myelogenous leukaemia; CGL, chronic granulocytic Ieukaemia; 'IV NeuAcnLqCer. NeuAca2-3(;al/~l-4GlcNAc/~I-3Gal/~l-4Glc-Cer; EL, erythroleukaemia; CLL, chronic lymphocytic leukaemia. papers, elevation of the enzyme activity in these patients, and its decline to normal values in clinical remission, were described (Chou et d., 1977; Khilanani et ul., 1977; Kessel et a/., 1980) . Another group reported completely opposite results, i.e. a decline of the serum enzyme activity in untreated patients and an increase of activity of the enzyme in remission (Kuhns et ul., 1980) . Activities of two other rx-L-fucosyltransferases present in human serum, i.e. of a-3-and cc-6-~-fucosyltransferase (EC 2.4.1.152 and EC 2.4.1.68 respectively), were also reported. Thus plasma rx-3-~-fucosyltransferase was found to be elevated in patients with chronic granulocytic leukaemia (CGL) (Kessel et a/., 1980) and those with non-Hodgkin's lymphoma (Khilanani et a/., 1978) . In the latter disease plasma enzyme activity was claimed to be correlated with estimated tumour burden (Khilanani PI ul., 1978) . The activity of a-6-~-fucosyltransferase was reported elevated in plasma of all individuals Vol. 15 receiving chemotherapy regardless of the disease status (Khilanani et al., 1978) .
It should be pointed out, however, that the exact cellular source and mechanism of entry of fucosyltransferases (and other glycosyltransferases) into blood plasma are largely unknown. Evidence is available that a-2-~-fucosyltransferase is entirely of bone marrow origin (Mulet et al., 1977) . On the other hand, haemopoietic tissue contributes only a part of serum glycosyltransferases specified by blood group A and B genes (Wrobel et al., 1974; KoScielak et al., 1976) .
Products of different a-L-fucosyltransferases are variably expressed in blood cells. Thus the Fuca 1 -2Gal structure (H antigen) is present in glycoconjugates of erythrocytes (for references see KoScielak, 1983) but not in those of granulocytes and lymphocytes Zdebska et al., 1985) . The structure GlcNAc was found in granulocytes (Zdebska et al., 1985) along with a-3-~-fucosyltransferase (Greenwell et al., 1983) activity. This structure is not present in a meaningful quantity in erythrocytes. Moreover, expression of fucose-containing glycoconjugates changes during the course of erythropoesis (for references see Fukuda, 1985) . Since leukaemias are basically clonal in origin, determination of serum a-Lfucosyltransferases may in theory be helpful for prognosis and even diagnosis of these diseases, providing it is known where the enzymes come from.
Here we report results of assays of a-2-, a-3-and a -6 -~-fucosyltransferases in sera of patients with AML and some other neoplastic diseases of haemopoietic tissue, i.e. of all three a-L-fucosyltransferases that are present in human serum. We also describe the source of serum a -6 -~-fucosyltransferase which is derived from blood platelets.
Materials and methods
Patients. The study was made on sera of 32 patients with various neoplastic diseases of haemopoietic tissue. The patients were diagnosed on the basis of accepted clinical and laboratory criteria. Control serum samples were obtained from normal blood donors. All samples were kept frozen at -20" C and were thawed only once just before transferase assays.
Radioactive nucleotide sugars and enzyme acceptors. Labelled GDP-['4C]fucose (200 mCi/mmol) was purchased from the Radiochemical Centre, Amersham, U.K. Phenyl-B-D-galactoside was from the Sigma Chemical Co. NeuAca2-3Gal~l-4GlcNAc~l-3Gal~l-4Glc-Cer (,IV NeuAcnLc,Cer) was isolated from human erythrocyte stroma by the method outlined previously (KoScielak et al., 1973) . The glycolipid was purified to homogeneity by h.p.1.c. with a Knauer HPLC apparatus (pumps, model 64, programmer, model 50) on a column (0.8 cm x 150 cm) packed with unmodified silica Lichrosorb Si 60, 10pm diameter (Merck), in chloroform. The column was eluted with chloroform/methanol/ water (10 : 80 : 10, by vol.) and chloroform/methanol/water (90 : 10 : 0.5, by vol.), programmed so that the concentration of the first solvent mixture increased from 20 to 60% final concentration.
IgG glycopeptide was isolated from pronase digests of human IgG (16g), product of the Institute of Haematology, Warsaw, Poland, by fractionation on Sephadex G-25, Sephadex G-75 and Dowex 50Wx2 (200-400 mesh) columns exactly as described by Narasimhan et al. (1979) . The main carbohydrate peak (containing approx. 85 mg of hexose and approx. lOmg of protein) eluted from Dowex 50Wx2 was desalted on a Bio-Gel P-10 column (1.5cm x 35cm) and then subjected to acid hydrolysis with 0.8 M-HCI at 80" C for 1 h to remove sialic acid, fucose and bisecting N-acetylglucosamine residues (Longmore & Schachter, 1982) . The material was again desalted on a Bio-Gel P-4 column (1.5 cm x 35 cm) and then exhaustively digested with jack bean B-galactosidase (Sigma) by the method of Li & Li (1 970). Briefly, the partially hydrolysed glycopeptide (80 mg) was treated with 0.4 ml of 0.2 M-citrate buffer (pH 4.0) and the enzyme (2ml, 4 units). The mixture was incubated for 8 h at 37" C. Subsequently, additional enzyme (1 ml) was added and the incubation was continued for 40 h under toluene. The mixture was then filtered successively through Bio-Gel P-4 (2cm x 30cm) and Bio-Gel P-10 (2cm x 30cm) columns and the appropriate hexosecontaining peaks were collected. The final eluate was evaporated under reduced pressure.
On the basis of methylation analysis employing g.1.c.-m.s. technique (for methods see Zdebska et al., 1985) it was concluded that the main component of the preparation was biantennary GnGn glycopeptide (Longmore & Schachter, 1982) which is terminated with two N-acetylglucosamine residues. Terminal galactose was not detected. This glycopeptide preparation will hence forth be referred to as stripped IgG glycopeptide. 2), 5pmol; neutralized ATP, 0.5pmol; NaN,, 0.8 pmol; serum, 50 pl. After 16 h incubation time at 37" C radioactive reaction product was isolated by the method A of Chester et al. (1976) and counted in a liquid scintillation counter.
a-3-~-Fucosyltransferase. The enzyme activity was measured under similar conditions to those described in . The incubation mixture contained in lOOp1: 'IV NeuAcnLc,Cer, 50 nmol; GDP-['4C]fucose, 0.5 nmol; Tris/HCl buffer (pH 7.0), 2.5 pmol; neutralized ATP, 1 pmol; MgCI,, 0.75pmol; NaN,, 0.75 pmol; Triton X-100, 100 pg; serum, 75 pl. Incubations lasted 24 h at 37" C and were terminated by sequential additions of 25 p1 of 0.2 M-EDTA (pH 7.2) and 1 ml of chloroform/ methanol (1 : I , v/v) solvent mixture. Samples were mixed, left overnight at room temperature and centrifuged at 2000 rev./min for 15 min. Supernatants were collected and residues washed once with 0.25ml portions of the chloroform/methanol ( 1 : 1, v/v) solvent mixture. Combined supernatants were dried under a stream of nitrogen and redissolved in 0.25 ml portions of chloroform/methanol/ 0 . 0 5~ aq. N H 4 0 H ( 5 : 5 : I , by vol.). The solubilized materials were spotted on Whatman 3MM papers and chromatographed overnight with 1 YO sodium tetraborate (pH 9. I). Radioactivity remaining at the origin and that of two adjacent 2cm x 2cm strips were determined by scintillation counting.
a-6-~-Fucosyltransferase. Incubation mixtures contained in 120 pl: stripped IgG glycopeptide, 1OOpg; GDP-['4C]-fucose, 0.37 nmol; sodium-cacodylate buffer, pH 6.0, 4 pmol; EGTA, 0.8pmol; MgCI,, 0.8pmol; NaN,, 1 pmol; serum, 25p1. After 16h at 37°C reactions were terminated by the addition of 80p1 of water and 200pl of absolute ethanol. Samples were mixed and clarified by centrifugation at 2000 rev./min for 15 min. Supernatants were withdrawn and tubes washed once with 200pl of 50% ethanol. Combined supernatants were passed through Dowex 1 (200-400 mesh) acetate columns (0.5cm x 1.5cm). The columns were washed successively with five 0.5 ml portions of 50% ethanol. Combined eluates were dried under a stream of nitrogen, redissolved in 200p1 of 50% ethanol and chromatographed overnight with absolute ethanol/O.Ol M aq. EDTA (8 : 2, v/v). Radioactivity remaining at the origin and that of two adjacent 2cm x 2cm strips was determined by liquid scintillation counting. Activity of cc-3-~-fucosyltransferase was studied with '1V NeuAcnLc,Cer, which is known to be a specific substrate for the enzyme (Johnson & Watkins, 1985; Hanson & Zopf, 1985) . The reaction was linear during at least 24h. Endogenous incorporation was negligible.
Results

Serum cc-2-~-fucosyltransferase was assayed in
a-6-~-Fucosyltransferase was studied with stripped IgG glycopeptide as substrate (see above and Longmore & Schachter, 1982) . The incorporation of ['4C]fucose into the glycopeptide was linear within the time limits of experiments. Endogenous incorporation of ['4C]fucose was negligible under conditions used for the assays of both a-3-and a-6-~-fucosyltransferases. In normal blood donors activity of cc-3-~-fucosyltransferase was lower in individuals of blood group A (mean 10.6 pmol of ['4C]fucose incorporated into acceptor substrate, S.D. 6.2, range 5.0-18.0, n = 6) than those of blood group B (mean 18.6, S.D. 9.1, range 11.3-39.9,n = 8 ) a n d O ( m e a n 2 1 . 3 ,~.~. 19.9.range8.&70.0, n = 8). There was no correlation of activity of u -~-Lfucosyltransferase and ABO blood groups (data not shown). Table 1 shows cc-3-and a-6-~-fucosyltransferase activities in 12 patients with AML who, with one exception, were different from those assayed for a-2-~-fucosyltransferase. Untreated patients exhibit 2-fold elevation of a-3-enzyme activity whereas low values are observed in patients under treatment with cytostatic drugs. The effect of the drugs on serum a-3-L-fucosyltransferase is long lasting since the enzyme activity stays low even in patients in whom chemotherapy was discontinued for 4-8 weeks before presentation. Activity of cc-3-enzyme is low also in patients in remission.
Activity of cc-6-~-fucosyltransferase is clearly low in all patients, especially those receiving chemotherapy. Higher enzyme values were, however, observed in patients in whom chemotherapy was discontinued or those in clinical remission. We attempted to correlate a-3-and c ( -~-Lfucosyltransferase activities with grossly abnormal granulocyte, lymphocyte and platelet counts as exhibited by some of our patients. The attempt was unsuccessful with c ( -~-Lfucosyltransferase (data not shown). There was, however, a definite correlation of a-6-~-fucosy~trdnsferase with platelet counts (see Fig. I ). a-6-~-Fucosyltransferase is almost absent in platelet-free plasma. Thus platelet-free plasma of two healthy individuals (T.P. and A.P.) yielded enzyme values amounting to only 11 and 7% respectively of those recorded for their sera. T o obtain platelet-free plasma, 
Range
Blood groups blood samples were collected with heparin as anticoagulant and then centrifuged at 3000 rev./min for 30min.
Discussion
Although this study was made with a limited number of patients, we can wholly confirm the results of Kuhns et al.
(1 980) of a diminution of a-2-~-fucosyltransferase activity in sera of patients with AML. The enzyme was also low in two patients with EL, the disease resulting most often from the proliferation of a malignant proerythroblastic clone (Wintrobe, 1981) . At this stage of erythropoesis ABO antigens are not yet well expressed (see Fukuda, 1985) . Thus a low a-2-~-fucosyltransferase activity in sera of patients with EL is not unexpected.
Serum a-3-~-fucosyltransferase activity seems to be elevated in untreated patients with AML but the enzyme activity is adversely affected by chemotherapy and stays low even in patients in remission. A low serum a-3-~-fucosyltransferase activity in blood group A donors cannot be explained at present. Obviously more sera should be studied.
Most interesting results were obtained on the activity of serum a-6-~-fucosyltransferase, which is clearly confined within intact platelets. Thus a low enzyme activity in sera of patients receiving chemotherapy is readily explained since platelet counts invariably fall during such treatment. It had previously been assumed that serum a-L-fucosyltransferase activities should reflect tumour burden and its cellular composition (Kessel et a / . , 1980; Kuhns et al., 1980 ). The present paper shows clearly that platelets are the major source of at least one a-L-fucosyltransferase. This finding as well as the reported presence of a-2-~-fucosyltransferase in blood platelets (Skacel & Watkins, 1987) may provide a clue for the conflicting reports on serum or plasma a-2-~-fucosyltransferase activity in AML patients Chou et Khilanani et al., 1977; Kessel et al., 1980; Kuhns et al., 1980) . Obviously our results and those of Kuhns et al., (1 980), who measured serum enzyme activity, are not comparable with the results of Kessel and co-workers (Chou et al., 1977; Khilanani et al., 1977; Kessel et al., 1980) , who performed assays on platelet-free plasma.
The Sd" determinant is the sole antigen of the Sid blood group system (see Race & Sanger, 1975) and is inherited as a Mendelian dominant character. Sd"-active materials are present in the blood and urine of 92% of the population, in another 4% these reactivities are weak or lacking, and the remaining 4% are true Sd(a-) individuals with anti-Sd" in their serum. As well as this, naturally occurring human Abbreviation used: T-H. Tamm-Horsfall.
anti-Sd", certain lectins, notably Dolichos biflorus, react with the Sd" antigen but are less specific. With such reagents cells from Sd( +) individuals are agglutinated to a different degree and may be classed as Sd(a+) or Sd(a+ +). A few extremely rare individuals have very strongly reacting cells and are classified as 'Cad' after the Mauritian family in which such cells were first observed (Cazal et al., 1968) . The exact genetic relationship between Cad and Sda has still to be established.
In urine the major carrier of the Sd" determinant has been shown (Morgan et al., 1979) to be the Tamm-Horsfall (T-H) glycoprotein (Tamm & Horsfall, 1950 ). Analytically, T-H glycoproteins from Sd(a +) and Sd(a -) individuals differ only in that the Sd(a+) samples contain 1-270 N-acetylgalactosamine whereas the Sd(a -) glycoproteins have less than 0.2%, indicating that this sugar is part of the Sd" determinant (Soh et al., 1980) . This finding reinforced earlier observations which showed that N-acetylgalactosamine inhibited the agglutination of Sd(a+) cells with
